Perrigo Company plc (PRGO) Earnings Call Transcript
November 5, 2025
Earnings Call Speaker Segments
Good morning, and good afternoon to all of you. Thank you for joining Perrigo's conference call covering our third-quarter 2025 earnings. I trust everyone had the opportunity to go through the 2 press releases we put out today. Both of those releases, along with the presentation for today's discussion, can be found in the Investors section on perrigo.com. With us on today's call are our President and CEO, Patrick Lockwood-Taylor, as well as our CFO, Eduardo Bezerra. I want to remind all of you that during this presentation, certain forward-looking statements will be made by participants. For information about these statements, which carry important risks and uncertainties, please refer to the slides; we will also reference adjusted financial measures that are non-GAAP in nature. Additional details, along with reconciliations of all non-GAAP to GAAP financial measures presented, can be found in the appendix to the earnings presentation. A few things before we begin. First, unless otherwise stated, all financial results we discuss and present are on a continuing operations basis. Second, organic growth does not include acquisitions, divestitures, exited products, or foreign currency fluctuations in either comparable period. Third, when it comes to the strategy reviews discussed today, no further updates will be provided unless and until the company determines that additional disclosure is appropriate or required. And finally, except as otherwise noted, Patrick's discussion will focus solely on non-GAAP results. With that, I'm happy to hand the call over to Patrick.
Thanks, Brad. Hello everyone, and I appreciate you joining today's call. First, I'd like to address recent developments in consumer health category consumption, which remains weak and mirrors the widespread near-term challenges in the marketplace. Despite this environment, Perrigo has continued to capture additional share and has advanced on crucial efforts within our Three-S plan: Stabilize, Streamline and Strengthen. Thanks to these actions, we can navigate this challenging environment while maintaining consistent advancement on our strategic goals and reinforcing our long-term value potential. Against that backdrop, let's examine how these patterns shaped our performance so far this year and what we expect going forward. We'll start with the U.S. OTC business, where Perrigo continued to deliver strong results despite a challenging market. Even though overall OTC consumption volume has declined in recent months versus a year ago, Perrigo's store brand has gained share for 6 months in a row. Those gains were driven by solid execution, shoppers moving away from national brands, new distribution, and competitive wins against major store brand rivals. Looking more closely, the right side of the slide shows that during the past 13 weeks, Perrigo gained 90 basis points of volume share, and this occurred in almost every OTC category where we compete, especially smoking cessation, allergy and women's health. We keep picking up share on volume even in this kind of market, which shows our OTC plan is working and proves to retailers and shoppers that we offer real value. Over in the EU, overall OTC spending in euros has been falling lately too. Even so, our main brands at Perrigo have been adding dollar share for five months straight, and that comes from having strong brands with distinctive value, plus our very targeted A&P spending on innovation and focused activation efforts. These gains have held up, which speaks to how well our category-led model works and how steady our key brands are — names like ellaOne, Jungle Formula, and our cough/cold lines, Physiomer and Coldrex. While the rest of our EU brands faced market-wide pressures similar to everyone else, the ones we've prioritized show just how solid our lineup really is. All told, the fact that Perrigo picked up share in both the U.S. and Europe — especially given how tough things are right now — speaks to how well we're executing and how much our distinctive OTC offering, with its multiple price tiers, matters to customers. With those gains in hand on both sides of the Atlantic, let's shift to what we've accomplished under our Three-S plan — Stabilizing, Streamlining and Strengthening — the framework that keeps shaping what we do and what we focus on. Our U.S. OTC store brand operation is now on stable footing, and within the categories where we play, we're beating the market. Like I said a moment ago, volume share has risen for six straight months. Pulling that off — expanding share again and again while the market stays tough — comes straight out of running the business with discipline, and it's plain proof that we're coming out ahead against competitors. Store brand has picked up share in infant formula too. On the operations side, parents and caregivers keep getting formula that's both safe and affordable from us, without interruption. Beyond that, we keep simplifying how the company is structured, operating as One Perrigo. Go back to 2022 — that's when we launched an effort to rebuild our supply chain from the ground up, and it remains on track to deliver between $150 million and $200 million in benefits once this year comes to a close. On the Energize initiative, we've achieved $163 million of gross yearly savings — that puts us past the midpoint of the $140 million to $170 million target band. On top of that, as we streamline, we've been reshaping the portfolio to make it more strategically scalable and better positioned when it comes to TSR. With these actions, Perrigo is getting back to what it does best: consumer health. We still expect the Dermacosmetics divestiture to wrap up during the first quarter of 2026. This morning, we shared that a review of the infant formula business is now underway, and I'll have more to say on that in a moment. In addition, our strategic review of the Oral Care business continues — that was something we told you about at the February Investor Day. We've made significant progress in making the company stronger. A fresh leadership group has been installed; we're developing new abilities for building brands on a large scale, and we've sharpened and improved how we innovate. If we roll out our commercial growth model, it ought to free up the entire portfolio's potential, enabling teams to bring more molecules to more shoppers in more geographies with greater efficiency. And finally, by leveraging consumer insights and collaborating more closely with our retail partners, we distinguish Perrigo in the marketplace. Operating this way is different, and everyone here is eager about the opportunities that lie ahead. Now let's look at quarter 3 and our results so far this year, during which our varied portfolio continued to demonstrate resilience despite difficult conditions. During Q3, our organic net sales dropped 4.4%. Of that, 1.6% came from the global OTC segment, largely because consumption in the OTC category was weak, while 2.8% stemmed from the businesses we're reviewing — Oral Care and Infant Formula. Gross profit and margin came in lower than last year, which mirrors how net sales performed. Prudent cost management helped partially cushion operating profit and margin. And, as we had anticipated, the Infant Formula scrap expense we saw in quarter 2 did not happen again, and that produced significant sequential growth in gross and operating margin — 180 and 380 basis points, respectively. All of this together resulted in third quarter EPS of $0.80, which is $0.01 higher than the prior year. So far this year, organic net sales have declined 1.7%. The main reason is a 0.8% hit from those businesses under review that I mentioned earlier, along with 0.5% because we don't have the stocking gains from last year's Opill launch. The rest of our OTC business accounted for the remainder. Even with the challenges in the marketplace, gross and operating margins have grown year-to-date, and organic operating income is up 13%, thanks to our ongoing work on accretive initiatives, improvement in Infant Formula, and careful cost control. EPS for the year-to-date is up 21%, or 27% on an organic basis, reaching $1.97. Consumer health consumption throughout the year-to-date has been volatile and hard to predict. We had year-over-year growth in Quarter 1. In Quarter 2, things turned from growth to decline during June, and that decline got much worse in the third quarter. The drivers appear transitory and don't look structural in nature. Taking into account refreshed assumptions regarding our Infant Formula business, those elements have driven us to adjust our 2025 outlook; for the long-term stewardship of Perrigo and our shareholders, this is the correct call. Within U.S. store brand OTC, across 5 of the 7 categories where we compete, Perrigo grew dollar unit and volume share. In Europe, our key brands, such as ellaOne, Jungle Formula, Compeed and our cough and cold franchise, likewise exceeded expectations. To seize this momentum, we redirected further A&P investments across both regions, producing roughly $30 million in sales beyond our initial forecast and yielding a solid return on investment. At the same time, consumption patterns in the market have been weaker than we had expected. During the most recent 13-week span, volume for the entire U.S. OTC category declined 3.2%, while Europe delivered just 0.6% growth — falling short of what we had originally assumed by roughly 700 basis points and 500 basis points, respectively. The result is an estimated $150 million to $170 million reduction to our 2025 net sales outlook. And lastly, although Infant Formula has steadied from an operational standpoint, store brand share will recover more slowly than we anticipated, and that, combined with distribution we lost for the Good Start brand, adds another $100 million of impact. Returning to Infant Formula: we announced today a strategic review of that business as we evaluate what role it should play in the Perrigo portfolio over the long term. We've gotten this business to a stable place, but conditions outside have moved fast. Keeping it strong will take ongoing funding and a lot of management attention, and that makes its long-term fit with our consumer health OTC portfolio—which grows faster and throws off more cash—less strategic. So in addition to putting a hold on the $240 million investment we announced earlier, the team will look at every option available. No matter where that review lands, what we're focused on as a company hasn't changed: cutting leverage, keeping the dividend intact, delivering for customers and shareholders, and concentrating on our high-potential OTC portfolio to widen consumer access and boost household penetration. While the review is underway, the business will continue running as usual, making sure customers and consumers get a steady, dependable supply of high-quality formula. In closing, we're carrying out our Three-S plan consistently, expanding our position in U.S. store brands while picking up share among our main European labels. What these outcomes show is how well our distinctive business model holds up, and they confirm the worth of what we offer even when consumption is weak. At the same time, we're realizing gains from reinventing our supply chain and from Project Energize. Beyond that, we're tightening our attention on consumer health, as shown by the announced divestiture of Dermacosmetics, and we're in the process of actively evaluating Infant Formula along with Oral Care. Even though weaker over-the-counter sales and Infant Formula are behind the change to what we expect for 2025, the traction we're getting from our Three-S plan and the market share we've picked up give us greater conviction that Perrigo can secure lasting demand for reliable consumer health products. At this point, I'll hand things over to Eduardo so he can take everyone through the financial results.
Thanks, Patrick, and good morning to all of you. Let's move on to how we performed financially in Q3, starting with the reconciliation between GAAP and non-GAAP figures. Several key items shaped our non-GAAP numbers: first, amortization costs came to $56 million; second, we recorded a $21 million restructuring charge, much of which relates to Project Energize as well as reinventing our supply chain; and third, litigation of an unusual nature accounted for $15 million. The full details appear in the non-GAAP reconciliation tables that accompany the press release we issued today. From here on, any financial figure I mention should be assumed to be adjusted unless I note otherwise. As Patrick noted earlier, softer consumption within the OTC category across both the U.S. and Europe put significant pressure on our top line results this quarter. Because he already walked through those drivers thoroughly, I'll begin my remarks with gross profit. For the third quarter, gross profit landed at $417 million, a decline of $30 million compared with last year, driven primarily by lower net sales as well as the effects of divestitures and products we exited. Partially offsetting those pressures were gains from reinventing our supply chain and currency translation that worked in our favor. Gross margin declined 110 basis points for the quarter due to those same factors, and this figure reflected a greater share of sales from store brands, which carry relatively lower margins, compared with our branded portfolio. On a year-to-date basis, gross profit reached $1.2 billion, which is $27 million below the prior year, and that includes a $40 million hit from divestitures and exited products. On an organic basis, gross profit didn’t change compared with a year earlier, even as gross margin improved by 60 basis points, driven by a rebound in infant formula and margin-accretive efforts. I’ll get to operating profit and earnings per share shortly. Moving now to net sales results across segments, beginning with CSCI. In the third quarter, organic net sales declined 5.3%, mainly because of weak consumption patterns in the OTC category, which was partially offset by gains in share for major brands and newly launched items. So far this year, organic net sales at CSCI are up 0.7%. The main reason is that we've got product supply back in place for Pain and Sleep, plus Healthy Lifestyle is growing thanks to big brands like Jungle Formula and NiQuitin. Those gains were partially canceled out by category consumption that started slowing down in Q2. Over at CSCA, third quarter net sales fell 3.8%. U.S. OTC was up 0.6%, helped by continuing share gains in 5 of our 7 store brand categories and by growth in our contract business. Upper Respiratory, Skin Care and Women's Health drove that growth, though Digestive Health and Healthy Lifestyle offset some of it. In OTC during the third quarter, growth was outweighed by declines across several areas: business under strategic review fell 4.4%, Infant Formula dropped 3.8%, and Oral Care slipped 0.6%. Looking at the year-to-date figures, CSCA net sales were down 3.1%, which reflects a 1.1% hit from business under strategic review along with the fact that last year's Opill launch stocking benefit of 0.8% didn't repeat. The rest of the OTC business declined 1.2%, since store brand share gains only partially compensated for ongoing weak market consumption. Operating income for the third quarter came in at $173 million, a decrease of $9 million. That 4.9% operating income decline was mainly driven by lower net sales flow-through as well as increased operating expenses in Infant Formula. That effect was partly counterbalanced by gains elsewhere in the portfolio, among them advantages from Project Energize along with disciplined expense control. Favorable currency translation entirely made up for divestitures and exited products. So far this year, operating income reached $455 million, a rise of $41 million, propelled by global OTC, upside from accretive initiatives, Infant Formula, and favorable currency translation, with divestitures and exited products providing partial offset. Organic operating income rose 13.2% during the period. Even with obvious difficulties in the marketplace, third quarter 2025 EPS came in at $0.80, versus $0.81 a year earlier. Earnings per share for the year to date were $1.97, an increase of almost 21%, or 27% on an organic basis. Now to the balance sheet and cash flow. Operating cash flow for the third quarter totaled $52 million, which lifted year-to-date operating cash flow to $63 million. Through the year to date, capital expenditures absorbed $67 million, and we returned $119 million to shareholders via dividends. Cash held on the balance sheet when the third quarter ended stood at $432 million. In light of our revised outlook, which I will walk through shortly, we now anticipate year-end net debt to adjusted EBITDA of roughly 3.8x, compared with our earlier goal of 3.5x, mainly because of our updated net sales expectations. We continue to expect the Dermacosmetics divestiture to close during the first quarter of 2026, and we intend to apply the net proceeds toward our deleveraging objective. In connection with the strategic review of the Infant Formula business that we announced, we have halted the previously announced $240 million investment while we establish the best path forward for that business. As a brief update, a strategic review of our Oral Care business is still in progress. Taking everything into account, and just like Patrick explained, we're updating our fiscal 2025 guidance. Instead of the low end of the organic net sales range we gave before, we now expect organic net sales growth of minus 2% to minus 2.5%. This shift comes from OTC category consumption being softer than we'd anticipated in both the U.S. and Europe, along with Infant Formula share growth coming in below what we'd expected. Given that top line change, our gross margin projection for the year is now roughly 39%. Even so, we're holding to an operating margin of approximately 15% for the year, because gains from accretive initiatives and tight cost discipline offset the gross margin revision. We're now looking at a slight gain for the whole year's tax rate, landing at about 18.5%. Those changes lead us to a 2025 EPS outlook between $2.70 and $2.80, which works out to growth of 5% to 9% versus 2024. Before I finish up, I want to touch on a few expectations for Q4 compared with the prior year. Starting with the top line, in our global OTC business we see organic growth of about flat to 1%, whereas our Nutrition category's sales are set to fall relative to last year, driven by reduced contract volumes and the overlap with restocking that happened in that same quarter a year earlier. Q4 margins should land below prior year levels, reflecting the effect of lower volumes and costs tied to tariffs. For the total company, operating expenses should be relatively flat year-over-year. To wrap up, we're up against a 14.9% tax rate from last year's Q4, while for the full year 2025 we're expecting something around 18.5%. In summary, the quarter showed the strength as well as the strains in our operations. Sales were held back by softer OTC consumption and a slower rebound in Infant Formula, yet we still achieved earnings per share growth of over 20% year to date along with double-digit growth in organic operating income. Margins are being maintained thanks to rigorous cost control and gains from our efficiency initiatives, and we continue to be dedicated to giving cash back to shareholders while bringing down leverage, which the pending Dermacosmetics divestiture supports. We revised our 2025 outlook to match today's conditions, but the steps we're taking to simplify the portfolio, keep costs in check and direct investments toward high-performing brands leave us confident that Perrigo can handle near-term difficulties and produce stronger, more lasting results as time goes on. Thanks, and now I'll hand the call back to Brad. Brad?
Thanks, Eduardo. Operator, can we please open the call for questions?
Maybe I'll just ask a quick follow-up about Infant Formula. It looks like there's quite a big gap, I suppose, between the sell-out figures and what you're selling in. I'm just wondering, was the main reason for that retailers reducing their inventory during the quarter? And I believe you mentioned that your share went up this quarter; and I was also wondering how the new SKUs you launched are performing? And more broadly, what actually caused the shortfall compared with what you had initially expected?
Susan, this is Eduardo. Let me offer a few thoughts. First off, indeed, our store brand share is rising; however, it's happening more slowly than we had initially planned, correct? So keep in mind, we had thought we'd reach the low 20s by the time the year ended. With the competitive landscape, we're still observing a lot of imported formulas entering the market; our store brand share is growing. So during Q3, we took a number of steps involving rollbacks and promotions to ensure we connect with consumers where they need us. That has played out, and we're noticing a meaningful — we've observed an uptick in our share, yet it's under what we had originally hoped for. And on that note, as a result, we're taking another look at our net sales guidance. Keep in mind, we mentioned in Q2 that we anticipated roughly 25% growth during the second half of the year. Due to that competitive pressure and also because market development there is slower, we're seeing a decrease on that front regarding the total market, which is affecting our share. One more key element, as you might recall, in Q4 of last year, we had a sizable contract volume sales. And as had been initially anticipated, those aren't coming through either, because of the new imports, the imports that are reaching the marketplace now.
Susan, you raised a question too about how quickly SKUs are moving. You really got it exactly right. Our rollout of new SKUs has gone according to schedule. What we're observing in terms of movement for those items falls short of what we expected. We know why, and those causes are getting corrected: where it sits on the shelf and how much shelf space Infant Formula store brand receives are both lower than they used to be. That hurts retailers' results and naturally ours as well, and we're working on it.
All right, that's helpful. Maybe I'll just ask one more thing about the CSCI business, looking at a few of those segments. In Women's Health, I believe you brought up certain supply limitations. I'm just wondering what caused those, and I believe that's now been fixed; then in VMS as well, I think you brought up how nutraceuticals have been deprioritized. So I'm wondering what's behind that; and then I think you also noted that consumption in VMS internationally was somewhat softer. I'm just wondering whether the consumer is somewhat stepping back from that category.
Yes. There are a few things going on. When we look at last year, correct? Last year, our Q3 was stronger. There were also a few early cough and cold signals last year, which differs from what we're seeing this year. So within CSCI, we anticipate a shift from Q3 into Q4. On your specific question about Women's Health, there were certain supply problems with our L1, which is the main brand we have in Europe there, but those have been worked out, and we anticipate that recovering in Q4. In VMS as well, yes, the nutraceuticals portfolio is one we've been deprioritizing in general relative to some of our brands, both in the Netherlands and Germany, that are doing fairly well. And then the final point on the soft OTC consumption, that's something we're observing more widely; but as we look toward Q4, when we point to our expectation of flat to 1%, we anticipate a meaningful pickup in CSCI relative to what we saw in Q3. So once again, last year, our Q3 was stronger than Q4. This year, we anticipate a shift due to seasonality, and also we expect more to happen in Q4 relative to what we saw in Q3 this year. That's why we're anticipating important sequential growth in CSCI, which is roughly 5% to 6% of net sales.
Keith, I want to ask whether you could give us a bit more detail about what shifted during the quarter for OTC and Infant Formula compared with what had originally been planned. You've already shared quite a lot, but the consumption volatility we keep seeing across many staples categories just doesn't look normal. So I'd like to know what you believe is behind it — is it greater pressure on consumers, perhaps a shift toward smaller pack sizes, and how have your discussions with retailers changed over the years?
Yes. Keith, regarding OTC consumption, we were back looking at that data yesterday; during quarter 1, consumption growth came in above what we had expected, somewhere between 3 and 3.5 points. During Q2 — I remember this — the information comes to us after the fact, just like it does for you. In that second quarter, things started to slow down, and then they shifted into a mild dip, with June essentially coming in level compared with both the prior year and the average of the last three; that pattern continued and honestly accelerated beginning in August, and consumption in October was soft as well, all right. So the situation has been shifting and very hard to forecast and without question weaker than what we and plenty of others had expected. Regarding Infant Formula, and I was just talking about this with Susan, the velocities we have seen have landed under our projections. Revenue has obviously taken a hit from this, and so has our share build, but we think there's a way to fix it. On your question about what's driving it, there are lots of tactical factors — future levels, display levels, certain distribution changes, certain pricing changes. In this category, we saw really strong price inflation over the last 2 to 3 years, which was building category value; that seems to have come to an end in quarter 1. You have seen trade move across into store brand, though. You know that store brand OTC is gaining share, and within that, we're gaining share too. This doesn't look structural. Looking at these treatment categories, incidence levels aren't really shifting, nor are generational shifts in consumption patterns. That does have some impact, though in my view it isn't significant, and definitely not in a major way. There's a hypothesis floating around that consumers are working through pantry inventory more aggressively than they typically would. Personally, I haven't come across figures that back that up, but the idea has been raised. Also, cough/cold season is clearly trailing where it stood a year ago up to this point, yet we're still anticipating a normal cough/cold season overall. To reiterate, there are numerous tactical elements at play, nothing we've observed indicates a structural shift, and consequently we'd anticipate the market returning to normal, which I believe some of our rivals have also mentioned.
Additionally, Keith, to build on Patrick’s remarks — unlike what I noted regarding CSCI, where we anticipate Q4 being better than Q3 — in comparison with how things went a year ago, we expect certain patterns to persist within U.S. OTC. A typical cough and cold season is what we’re looking for. Yet measured against last year, Q4 is expected to decline. So the overall impact of the 0 to 1% figure amounts to roughly 5% to 6% positive on the CSCA side, while it’s negative in the U.S., even with all the distribution and share gains we’re observing there. What also matters greatly is the decrease we’re seeing in Infant Formula, which plays a major role in driving that outcome, due to — as I said — reduced contract volumes along with a slower rate of recovering our store brand share within the Infant Formula business.
Understood — that's a big help. If there's room for one more question, I'd like to know how you're approaching reinvestment plans. With consumption in OTC having pulled back, and now the Infant Formula investment being paused, are there any places where you'd want to spend more? Clearly there are some green shoots, with new business wins, and then of course international. So I'm curious how you might think about possibly reallocating spend down the road.
Yes. Keith, I'll go first, then Eduardo. Like I said in my comments, the same priorities hold for us: deleverage, maintain our dividend. That said, we'll take another look at investing in organic growth, all right? We're seeing more and more proof of businesses that are performing — U.S. store brand. You're right to bring up the share growth acceleration we're seeing in our key international branded business, plus our brands in the U.S. There's likely a chance to speed up revenue on those, okay? Still, we have to examine every business case and every one of our priorities and figure out what's best, clearly, for the asset over the long term, and also for shareholders; so yes, given the decision we've made on Infant Formula, we'll be doing another review of capital allocation. But those priorities will stay the same. We might just raise the amount on certain of those allocations. Eduardo?
That's all I've got, Keith.
Ethan here, filling in for Chris Schott. To kick things off, perhaps building on a few of the earlier questions. I was curious about the current position of Infant Formula share. Then, thinking about 2026, how do you view the business's capacity to win back share, and what would the priorities be for that?
Yeah. Appreciate the question. From where I sit, we've observed — we're sitting at roughly 16% share. There are definite building blocks in place to keep expanding that during '25 and on into '26; and with those building blocks, my expectation across the coming 12 months is that you land in the 18% to 20% range when it comes to share.
Also, it's worth bringing up once more what we shared earlier today regarding the strategic review of our infant formula business, correct? We're examining a number of possibilities for how we might approach that operation, ensuring we get the most out of it, both in the short run and over the longer haul, and making certain this delivers the strongest outcome for shareholders as well.
Great, and that's all I have. As we look toward 2026 overall, I realize it's early, but I was hoping you might share how you're weighing the various positive and negative forces in the business, and perhaps the capacity to expand EBITDA as we head into next year.
Sure. Let me offer a few thoughts. We're at an early point in the planning cycle, correct? So giving specifics now would be premature, though we are currently examining certain headwinds and tailwinds, correct? Once more, as Patrick pointed out, our view is that the OTC market has not suffered structural damage. What we observe is essentially a near-term hit to consumption. Thus, we anticipate stabilization in 2026. More specifically, we expect something along the lines of flat to modest percentage growth. Having said that, our expectation remains that we keep gaining share and that this also converts into expansion somewhat above the market rate. Turning to Infant Formula, overseas producers have increased their U.S. share. Therefore we are focused on ensuring we stick with our strategy to win back our share, while simultaneously recognizing that additional unused domestic capacity in the U.S. will affect absorption for local players. Furthermore, we are dealing with the stranded cost effect from our Dermacosmetics divestiture, correct? We anticipate completing that transaction by the end of Q1. As a result, we foresee roughly 9 months of inorganic headwind amounting to about $100 million on our top line. And based on when the close occurs, that will produce some net EPS effect on our bottom line.
The second factor is momentum—compared with this year, our innovation pipeline is getting noticeably stronger. On top of that, our brand initiatives keep getting better, whether that means fresh advertising, new packaging, or expansion into additional markets. So the things behind our share gains are, in our view, picking up speed across a wider set of categories, brands, and geographies, backed by still more innovation.
About that 110 basis points of gross margin pressure this quarter — from what I'm hearing, sales deleverage and mix were the main drivers, and it doesn't seem like input costs or competitive pricing moves played a role. Is that accurate?
Yes, you've got that right.
Regarding the expected margin hit from tariffs, which you put at $40 million to $50 million — that figure is prior to any mitigation actions, correct? But could there be some delay between when you implement higher prices and when those costs actually hit?
No, we don't anticipate any delay there. As we mentioned, work on this has been underway since the start of the year, and our expectation is that 1/3 comes through pricing, with the rest coming from various manufacturing steps we're taking, whether in sourcing or seeking additional suppliers; so those efforts are already in motion. We're already seeing some margin impact in Q4, though a significant portion is being offset by pricing, and that will carry forward into 2026.
All right. Do you anticipate any competitive shifts, with some producers bringing goods in from abroad or getting them locally? Or do you foresee any kind of market share movement from that in '26?
It's really been a highly fluid situation, especially with the latest announcement regarding tariffs on China, correct? So we keep assessing that. Yet as we keep observing our robust standing and substantial manufacturing here in the U.S., you can see that showing up as gains in our share, right? Given the powerful position we hold in the market, we keep anticipating that will speed up as we enter 2026, since we're building more strategic partnerships and joint business plans with our major retailers, because in a period like this, when consumers are trading down, they look to us for help growing. They need to ensure there's sufficient optionality with store brand, and that's exactly where we think we can deliver a great deal of value. So, I'm not sure — Patrick, anything to add there?
No.
Thanks so much, and I appreciate those questions as well as your time with us today. So I'll offer just a handful of closing thoughts. Clearly, to begin with, market conditions are extremely challenging, with consumption far weaker than anybody could reasonably have anticipated. We've needed to change direction in response. Even so, in that setting, we're beginning to come out ahead. Not in many years have we grown share until now, and the pace of that growth exceeds what we had expected. That said, our financial results, given soft market conditions along with where our Infant Formula business stands and how it's performing, honestly aren't where we'd like them to be. Adjustments will keep being made to fix that and to position us for a successful 2026. Today we announced the launch of a strategic review covering our Infant Formula business. The purpose is to sharpen focus on our scalable OTC platform. And naturally, whatever effect that strategic review has on our 2027 outlook will be shared after the review wraps up. As I said, we stay committed to deleveraging, with a target below 3.5x and the Dermacosmetics proceeds directed toward reducing debt. A substantial growth opportunity lies ahead by extending our unmatched molecule asset base into additional price points, brands and markets. We're deepening strategic retail partnerships further to generate mutual demand, and our spending on brand building, innovation, digital and analytics is powering our increasingly winning formula. Our goal is to keep growing share via superior consumer propositions and brand experiences plus disciplined execution, with a focus on driving cash flow and total shareholder return. Once again, thank you so much for joining us today.
Appreciate it. That wraps up the conference call for today, everyone. Thanks to each of you for being on the line. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Perrigo Company plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Perrigo Company plc earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.